Recommended MME for Non-Cancer Chronic Pain
For adults with chronic non-cancer pain, start at 20-30 MME/day, carefully reassess before increasing to ≥50 MME/day, and avoid exceeding 90 MME/day unless you can clearly justify that benefits outweigh risks based on individualized assessment.
Starting Dose
When initiating opioids in opioid-naïve patients with chronic pain, begin with 20-30 MME/day 1. The 2022 CDC guideline specifies that the lowest starting dose is often equivalent to approximately 5-10 MME as a single dose or 20-30 MME/day 1.
Critical Dosage Thresholds
The 50 MME/day Threshold
Before increasing total opioid dosage to ≥50 MME/day, pause and carefully reassess evidence of individual benefits and risks 1. This is a critical decision point because:
- Many patients do not experience benefit in pain or function from increasing opioid dosages to ≥50 MME/day 1
- Progressive increases in risk occur as dosage increases 1
- Additional precautions are required at this level, including increased frequency of follow-up and considering offering naloxone 2
If you decide to increase dosage beyond 50 MME/day, use caution and increase by the smallest practical amount 1.
The 90 MME/day Threshold
Avoid increasing dosage to ≥90 MME/day or carefully justify a decision to titrate to this level 2. The 2016 CDC guideline explicitly states to "avoid increasing dosage to 90 MME or more per day" 2, while the updated 2022 guideline emphasizes avoiding dosage increases above levels likely to yield diminishing returns in benefits relative to risks 1.
Additional dosage increases beyond 50 MME/day are progressively more likely to yield diminishing returns in benefits for pain and function relative to risks 1.
Key Algorithmic Approach
- Start low: 20-30 MME/day for opioid-naïve patients 1
- First checkpoint at 50 MME/day: Pause, reassess benefits vs. risks, implement additional precautions 2, 1
- Second checkpoint at 90 MME/day: Generally avoid; if considering, must carefully justify based on individualized assessment 2, 1
- If no improvement at ≥90 MME/day: Discuss other approaches, consider tapering, consider pain specialist consultation 2
Supporting Evidence from Other Guidelines
The Japanese Society of Pain Clinicians guideline recommends an upper limit of 90 MME/day for chronic non-cancer pain 3, which aligns with CDC recommendations. German data demonstrates that guideline-recommended doses (<120 mg MEQ/day) are associated with better health outcomes compared to high-dose therapy, including lower rates of risky prescribing, fewer hospital admissions for abuse/addiction, and lower healthcare costs 4.
Important Caveats
- These thresholds are guideposts, not inflexible standards 1. Risks increase continuously with dosage, and there is no single threshold below which risks are eliminated 1
- The recommendations apply specifically to starting opioids or increasing dosages; different considerations apply to reducing opioid dosages 1
- For established patients already on high doses (≥90 MME/day), offer the opportunity to reevaluate continued use in light of evidence regarding overdose risk 2
- Dosages ≥100 MME/day are associated with almost 9-fold increased risk of overdose 5
Practical Implementation
When prescribing at any dosage level:
- Use caution at any dosage 1
- Generally avoid dosage increases when possible 1
- Continually reassess maintenance of pain control, adverse reactions, and development of addiction, abuse, or misuse 6
- Weigh factors such as diagnosis, incremental benefits for pain and function relative to risks with previous dosage increases 1